American Heart Association Journals Circulation Representing the best in the field of cardiovascular medicine and science as well as basic science Editor-in-Chief: Joseph A Hill, MD, PhD View latest issue
2026 ACC AHA AACVPR ABC ACPM ADA AGS APhA ASPC NLA PCNA Guideline on . . . A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline
2026 AHA ACC ACCP ACEP CHEST SCAI SHM SIR SVM SVN Guideline for the . . . Category E1 is compatible with SCAI SHOCK stage C 3 Category E2 is defined by refractory cardiogenic shock (SCAI D-E) or cardiac arrest without restoration of spontaneous circulation after 30 minutes of resuscitation Respiratory failure in category E-R is defined by the need for noninvasive or invasive positive pressure ventilation
Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment . . . Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS
2025 ACC AHA HRS ISACHD SCAI Guideline for the Management of Adults . . . The biventricular circulation and systemic left ventricle share the greatest anatomic and physiological similarities with heart failure patients in clinical trials; extrapolation from the heart failure literature is most appropriate in this population
| AHA ASA Journals Circulation publishes original research manuscripts, review articles, and other content related to cardiovascular health and disease, including observational studies, clinical trials, epidemiology, health services and outcomes studies, and advances in basic and translational research
Risk-Based Primary Prevention of Heart Failure: A Scientific Statement . . . The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice First, the 2022 American Heart Association American College of Cardiology Heart Failure